NIH | National Cancer Institute | NCI Wiki  

This meeting was cancelled.

Date

Attendees

Committee MemberPresentAbsent
Kuffel, Gina (NIH/NCI) [C]
X

Unknown User (leblancak)


X

Otridge, John (NIH/NCI) [C]



Kim, Erika (NIH/NCI) [E]


Sommers, Connie (NIH/NCI) [E]



Debbie Knapp

Toby Hecht

Unknown User (parchmentr)



Goals

  • Discuss updates to ICDC and define emerging strategies and priorities

SharePoint Site

https://nih.sharepoint.com/sites/NCI-CBIIT-FNL-ICDC-ICDCLeadershipGroups

Outstanding Action Items

  • Toby to work on outline for RFI

Agenda

ItemWhoTalking Points
DGAB Updates

Kuffel, Gina (NIH/NCI) [C]

  • 33 TB of data are now available in ICDC (five-fold increase since January)
  • TCL01: A multi-omics analysis of canine mammary cancer
    • File transfer is complete
    • Metadata loaded onto Dev tier
    • Manifest sent to DCF team for indexing
    • Pending release record to be visible in production soon
  • 1st PRECINCT study has been approved by the DGAB & SAC
  • PRECINCT has used templates available from the ICDC Data Model Explorer (DME) for the first ever load of a study via submitter-generated loading files
    • Initial version of data is available in Dev tier
  • Will has volunteered his time to create a scientific use case from ICDC data
  • New data submission request from Dawn Duval’s group: “Immune Pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma”. (26 tumor normal pairs)
BPSC Updates

Kuffel, Gina (NIH/NCI) [C] 

  • 2022 BPSC Review Article
    • Outline completed
    • Preliminary section assignments have been made
    • Deadline for section drafts is August 22nd
July Steering Committee Updates

Unknown User (parchmentr)

  • Minutes to be posted
  • Next meeting is August 24th
ICDC Site Updates

Kuffel, Gina (NIH/NCI) [C]

  • New software version released on July 11th
    • ICDC Static News Page
    • Data Availability Landscape (DAL)
    • Gene annotations for JBrowse
ICDC Next Phase Planning

Unknown User (hechtt)

Minutes (Not Verbatim)



Previous ICDC Use Cases from Steering Committee

1. Genomic correlates across platforms (DNA, RNA, protein).

2. Correlating multi-omics data with clinical annotation and phenotypes, particularly outcomes.

3. Comparative analyses of canine and human. Examples include:

1. Search for conserved mutations between canine and human tumors

2. Disease diagnosis (e.g. cancer type) and classification mapping between canines and humans

5. Gene expression changes and mutational profiles associated with therapeutic response and outcome

6. How do sporadic tumors in non-human mammals compare to sporadic human tumors?

7. Correlations and model building from radiomic and pathomic features extracted from medical and histopathologic images with outcomes and genomics, as is currently being widely done with human images

8. Develop biomarkers of response and resistance in humans by analyzing the responses and genomic signatures in dogs.

Previous Meeting Minutes (Not Verbatim)

Toby- Understanding of RFI is to go out ask for people doing comparative oncology across humans and dogs research to come up with questions or case studies or hypotheses that can leverage data in the ICDC to answer these question to expose gaps of data to inform the type of data we would like to source in the future.

DK- To identify key questions and if ICDC can help to answer these questions.

Toby- Who will be the PoC? I will do an outline of this and then circulate to this to the Executive Team.

JO - Executive TEam and then polish for broader dissemination to the Steering Committee.

Toby- We can send out to the Cancer Centers

AL - We can encourage all to share broadly 


Action item